Reimbursement Act had a strong impact on the pharma distribution segment in Poland

23 April 2013

In 2012, the pharmacy distribution market in Poland saw a decline for the first time in several years, reporting negative growth of -6%. Companies operating in the pharmaceutical market are poised to recover their market positions throughout 2013 after the revolution triggered by the entry into force of the Reimbursement Act.

Given a low base of comparison, sales are expected to increase, though many companies will struggle to survive, according to the latest report of PMR, a Poland-based research and consulting company, titled Distribution on the pharmaceutical market in Poland 2013. Impact of the Reimbursement Act and development forecasts for 2013-2015.

Reimbursement Act and its implications

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >